Hence, owing to mutations in FH, SDH and L2HGDH genes, which lead to TET and KMDs inhibition, aberrant accumulation of oncometabolites occurs in RCC, stimulating tumor growth and aggressiveness (Figure 5B) [148,149]. This evidence concerns the gene L2HGDH and renal cell carcinoma.